Search research articles
Contact Us
Filters
Showing results (61-70 of 136) with videos related to
Page
of 14
Sort By:
Therapeutic Advances in Medical Oncology
|
July 2, 2019
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
Robert Wesolowski, Neelesh Sharma, Laura Reebel, et al.
Oncoimmunology
|
October 21, 2016
Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator
Prashant Trikha, Robert L Plews, Andrew Stiff, et al.
Plos One
|
March 31, 2023
A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship
Annelise A Madison, Marie Filatov, Rebecca Andridge, et al.
The Lancet. Oncology
|
March 28, 2024
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Rachel M Layman, Hyo S Han, Hope S Rugo, et al.
Oral Oncology
|
December 20, 2023
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
Renata Ferrarotto, Paul L Swiecicki, Dan P Zandberg, et al.
Frontiers in Oncology
|
April 10, 2026
Case Report: Late choroidal metastasis from hormone receptor-positive, HER2-negative breast cancer responsive to first-line endocrine therapy
Hisham Alsharif, Robert Wesolowski, Colleen M Cebulla, et al.
Investigational New Drugs
|
February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
Afshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Cancer Medicine
|
June 19, 2024
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Jasmine S Sukumar, Sagar Sardesai, Andy Ni, et al.
JACC. Case Reports
|
May 9, 2025
Pembrolizumab-Induced Smoldering Myocarditis in Patients With Triple-Negative Breast Cancer
Adnan Shaaban, Alma Habib, Dionisia Quiroga, et al.
Clinical Breast Cancer
|
June 8, 2025
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer
Stefania Morganti, Xiangying Chu, Tarah J Ballinger, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 136) with videos related to
Sort By:
Page
of 14
Therapeutic Advances in Medical Oncology
|
July 2, 2019
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
Robert Wesolowski, Neelesh Sharma, Laura Reebel, et al.
Oncoimmunology
|
October 21, 2016
Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator
Prashant Trikha, Robert L Plews, Andrew Stiff, et al.
Plos One
|
March 31, 2023
A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship
Annelise A Madison, Marie Filatov, Rebecca Andridge, et al.
The Lancet. Oncology
|
March 28, 2024
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Rachel M Layman, Hyo S Han, Hope S Rugo, et al.
Oral Oncology
|
December 20, 2023
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
Renata Ferrarotto, Paul L Swiecicki, Dan P Zandberg, et al.
Frontiers in Oncology
|
April 10, 2026
Case Report: Late choroidal metastasis from hormone receptor-positive, HER2-negative breast cancer responsive to first-line endocrine therapy
Hisham Alsharif, Robert Wesolowski, Colleen M Cebulla, et al.
Investigational New Drugs
|
February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
Afshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Cancer Medicine
|
June 19, 2024
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Jasmine S Sukumar, Sagar Sardesai, Andy Ni, et al.
JACC. Case Reports
|
May 9, 2025
Pembrolizumab-Induced Smoldering Myocarditis in Patients With Triple-Negative Breast Cancer
Adnan Shaaban, Alma Habib, Dionisia Quiroga, et al.
Clinical Breast Cancer
|
June 8, 2025
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer
Stefania Morganti, Xiangying Chu, Tarah J Ballinger, et al.
Page
of 14